Unicancer Innov
NewsRoom News
Fr En
Home - Research area - Clinical Research - Unicancer clinical trials

Unicancer clinical trials

Filter by

En cours d'ouverture

Expert group : Med Perso

  • Endomètre
  • Colon
  • Tête et cou
  • Poumon
  • Sarcome

AcSé HER2 / zanidatamab

Widening treatment options among adult patients with HER2-overexpressing or mutant solid cancers

Principal investigator : Dr Barbara PISTILLI

Etude Phase II

Sponsor : UNICANCER

Unicancer Contact Marta JIMENEZ

Find out more about the study

En cours de recrutement

Expert group : MED PERSO

  • Sein

SAFIR03 SCREENING/ARRIBA

A ctDNA screening program in patients with HR+, HER2 negative metastatic breast cancer for detection of high-risk relapse patients on any CDK4/6 inhibitor and a randomised phase II study comparing alpelisib combined with fulvestrant to ribociclib combined with fulvestrant, in patients with persistent targetable PIK3CA mutations

Principal investigator : Pr Fabrice André

Etude Phase II

Sponsor : UNICANCER

Unicancer Contact Marta JIMENEZ

Find out more about the study

En cours de recrutement

Expert group : MED PERSO

  • Voies biliaires

SAFIR ABC10

Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomised, controlled, open-label, platform phase 3 trial

Principal investigator : Dr David MALKA

Etude Phase III

Sponsor : UNICANCER

Unicancer Contact MARTA JIMENEZ

Find out more about the study

En cours de recrutement

Expert group : SARCOME

  • Utérus

L-UTECIN

Interest of adjuvant chemotherapy in patients with CINSARC high-risk localized resected uterine leiomyosarcoma

Principal investigator : Pr Florence DUFFAUD

Etude Phase II

Sponsor : UNICANCER

Unicancer Contact Marta JIMENEZ

Find out more about the study

En cours de recrutement

Expert group : UCGI

  • Colorectal

UCGI 29 / PRODIGE 52 - IROCAS

A Phase III, Randomised, international trial comparing mFOLFIRINOX triplet chemotherapy to mFOLFOX for high-risk stage III colon cancer in adjuvant setting

Principal investigator : Dr BENNOUNA Jaafar

Etude Phase III

Sponsor : UNICANCER

Unicancer Contact MONARD Laure

En cours de recrutement

Expert group : MED PERSO

  • Sein

TRAKER

A randomised trial of early detection of molecular relapse with circulating tumour DNA tracking and treatment with palbociclib plus fulvestrant versus standard endocrine therapy in patients with ER positive HER2 negative breast cancer

Principal investigator : Pr Fabrice André

Etude Phase II

Unicancer Contact Marta JIMENEZ

Find out more about the study

En cours de recrutement

Expert group : UCBG

  • Sein

SASCIA

Phase III postneoadjuvant study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment

Principal investigator : Pr Anthony GONCALVES

Etude Phase III

Sponsor : GBG

Unicancer Contact LEMONNIER Jérôme

En cours de recrutement

Expert group : UNITRAD

  • Tumeur solide

STEREO-OS

Extracranial Stereotactic Body Radiation Therapy (SBRT) added to standard treatment versus standard treatment alone in solid tumors patients with between 1 and 3 bone-only metastases

Principal investigator : Dr THUREAU Sebastien

Etude Phase III

Sponsor : UNICANCER

Unicancer Contact LAMRANI - GHAOUTI Assia

En cours de recrutement

Expert group : GETUG

  • Cellules germinales

TIGER GETUG AFU-27 / ALLIANCE A031102

A randomized phase III Trial comparing conventional-dose chemotherapy using PACLITAXEL, IFOSFAMIDE, and CISPLATIN (TIP) with high-dose chemotherapy using mobilizing PACLITAXEL PLUS IFOSFAMIDE followed by high-dose CARBOPLATIN AND ETOPOSIDE (TI-CE) as first

Principal investigator : Dr FLECHON Aude

Etude Phase III

Sponsor : Alliance

Unicancer Contact LEGER Catherine

123 ... 202122>>